Veracyte Completes Acquisition of C2i Genomics
Extends Veracyte’s novel diagnostics platform with whole-genome minimal residual disease capabilities Expands company’s presence across the cancer care continuum SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer … Continue reading Veracyte Completes Acquisition of C2i Genomics